Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

ONC001: A first-in-class ADC targeting CD64 for the treatment of monocytic leukemia developed through patient-guided target and payload selection

Blood (2025) 146 (Supplement 1): 324.

https://doi.org/10.1182/blood-2025-324

Published: 2025

Journal Articles

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfo, Persefoni Talimtzi, Maria Angelopoulou, Tomas Arpas, Laura Ballotta, Leonidas Benetatos, Ana Margarida Bertolo, Horia Bumbea, Maurizio Cavallari, Anastasia Chatzidimitriou, Dominik Chraniuk, Anna Christoforidou, Francesca Cibien, Antonio Cuneo, Maria Ilaria del Principe, Marina Deodato, Enrico Derenzini, Michael Doubek, Fabiana Esposito, Lucia Farina, Gianmarco Favrin, Isacco Ferrarini, Annamaria Frustaci, Andrea Galitzia, Massimo Gentile, Iulia Roxana Iancu, Vanessa Innao, krzysztof jamroziak, Elzbieta Kalicinska, Maria Kislova, Ioannis Kyriakou, Luca Laurenti, Enrico Lista, Javier Loscertales, Alexandros Machairas, Giorgia Marcato, Francesca Martini, Nilla Maschio, Eva Minga, Riccardo Moia, Roberta Murru, Maura Nicolosi, Jacopo Olivieri, Carolina Pavlovsky, Miguel Pavlovsky, Sara Pepe, Ernesto Perez Persona, Giuseppe Petruzzellis, Gian Matteo Rigolin, Alessandro Sanna, Marina Siakantaris, Paolo Sportoletti, Oana Stanca, Niki Stavrogianni, Tamar Tadmor, Annamaria Tomasso, Marzia Varettoni, Theodoros Vassilakopoulos, Eva Gimeno Vazquez, Candida Vitale, Mohamed Yassin, Mihnea Zdrenghea, Klaudia Zielonka, Livio Trentin, Kostas Stamatopoulos, Paolo Ghia

Blood (2025) 146 (Supplement 1): 6287.

https://doi.org/10.1182/blood-2025-6287

Published: 2025

Journal Articles

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

Blood (2025) 146 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2025-1993

Published: 2025

Journal Articles

Integrating cytokine profiles with clinical and molecular biomarkers to predict molecular relapse after TKI discontinuation in CML patients

Blood (2025) 146 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2025-3785

Published: 2025

Journal Articles

Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study

Blood (2024) 144 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2024-200017

Published: 2024

Journal Articles

Assessing Molecular Relapse-Free Survival in Latin American Chronic Myeloid Leukemia Patients Undergoing TKI Dose Reduction

Melina Gisel Luft, Ricardo Khalil Tannuri, María Jose Mela Osorio, Maria Elisa Riva, Beatriz Moiraghi, Ana Ines Varela, Ana Inés Prado, Veronica Ventriglia, Maria Josefina Freitas, Olivia Maria Gelo, Federico Sackmann Massa, Maria Fernanda Tosin, Mariel Ana Perez, Mariana Stevenazzi, Victoria Matosas, Carolina Barreto, Miguel Arturo Pavlovsky, Isolda Isabel Fernandez, Carolina Pavlovsky

Blood (2024) 144 (Supplement 1): 6620.

https://doi.org/10.1182/blood-2024-209195

Published: 2024

Journal Articles

Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 3149.

https://doi.org/10.1182/blood-2024-205681

Published: 2024

Journal Articles

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Blood (2024) 144 (Supplement 1): 3148.

https://doi.org/10.1182/blood-2024-207634

Published: 2024

Journal Articles

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2023) 142 (Supplement 1): 3164.

https://doi.org/10.1182/blood-2023-178790

Published: 2023

Journal Articles

Functional Ex-Vivo Testing Combined with Machine Learning Predicts Clinical Response to Azacitidine+Venetoclax in AML

Blood (2023) 142 (Supplement 1): 2274.

https://doi.org/10.1182/blood-2023-187284

Published: 2023

Journal Articles

Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

Blood (2023) 142 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2023-189797

Published: 2023

Journal Articles

Long-Term Follow-up of the AST Trial of Treatment-Free Remission in Chronic Myeloid Leukemia Patients

Blood (2023) 142 (Supplement 1): 6365.

https://doi.org/10.1182/blood-2023-189393

Published: 2023

Journal Articles

Identification of Unexpected Responders to Gilteritinib in a Cohort of FLT3-WT AML Patients Using Ex-Vivo Testing

Blood (2023) 142 (Supplement 1): 7132.

https://doi.org/10.1182/blood-2023-181119

Published: 2023

Journal Articles

Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

Maria Agustina Perusini, Camille Kockerols, Daniela Žáčková, Franck E. Nicolini, Fausto Castagnetti, Carolina Pavlovsky, Massimo Breccia, Delphine Rea, Carmen Fava, Mary Lynn Savoie, Christophe Bouvier, Petra Čičátková, Julien Bollard, Swe Mar Linn, Gopila Gupta, Emilia Scalzulli, Jiří Mayer, Peter E Westerweel, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 6360.

https://doi.org/10.1182/blood-2023-190293

Published: 2023

Journal Articles

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Blood (2022) 140 (Supplement 1): 6774–6775.

https://doi.org/10.1182/blood-2022-168228

Published: 2022

Journal Articles

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Blood (2022) 140 (Supplement 1): 6760–6762.

https://doi.org/10.1182/blood-2022-157956

Published: 2022

Journal Articles

Ex-Vivo Testing Using Patient Micro Avatars (PMAs) Predicts Clinical Response in Acute Leukemias

Blood (2022) 140 (Supplement 1): 13027–13028.

https://doi.org/10.1182/blood-2022-164847

Published: 2022

Journal Articles

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Blood (2022) 140 (Supplement 1): 6782–6783.

https://doi.org/10.1182/blood-2022-167927

Published: 2022

Journal Articles

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2022) 140 (Supplement 1): 1495–1497.

https://doi.org/10.1182/blood-2022-157822

Published: 2022

Journal Articles

Economic Impact Analysis of Treatment-Free Remission in Chronic Myeloid Leukemia Patients with Sustained Deep Molecular Response in the AST-2018 Trial

Blood (2022) 140 (Supplement 1): 5088–5089.

https://doi.org/10.1182/blood-2022-162407

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

ONC001: A first-in-class ADC targeting CD64 for the treatment of monocytic leukemia developed through patient-guided target and payload selection

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

Integrating cytokine profiles with clinical and molecular biomarkers to predict molecular relapse after TKI discontinuation in CML patients

Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study

Assessing Molecular Relapse-Free Survival in Latin American Chronic Myeloid Leukemia Patients Undergoing TKI Dose Reduction

Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Functional Ex-Vivo Testing Combined with Machine Learning Predicts Clinical Response to Azacitidine+Venetoclax in AML

Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

Long-Term Follow-up of the AST Trial of Treatment-Free Remission in Chronic Myeloid Leukemia Patients

Identification of Unexpected Responders to Gilteritinib in a Cohort of FLT3-WT AML Patients Using Ex-Vivo Testing

Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Ex-Vivo Testing Using Patient Micro Avatars (PMAs) Predicts Clinical Response in Acute Leukemias

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Economic Impact Analysis of Treatment-Free Remission in Chronic Myeloid Leukemia Patients with Sustained Deep Molecular Response in the AST-2018 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only